Verastem Inc (NASDAQ:VSTM) – Analysts at B. Riley issued their FY2017 earnings per share estimates for Verastem in a research report issued on Thursday. B. Riley analyst G. Zavoico forecasts that the biopharmaceutical company will post earnings per share of ($1.72) for the year. B. Riley currently has a “Buy” rating and a $15.00 target price on the stock. B. Riley also issued estimates for Verastem’s Q4 2017 earnings at ($0.39) EPS, Q1 2018 earnings at ($0.37) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.38) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.45) EPS, FY2019 earnings at ($0.94) EPS, FY2020 earnings at ($0.12) EPS, FY2021 earnings at $0.58 EPS and FY2022 earnings at $1.58 EPS.
A number of other research firms have also recently weighed in on VSTM. Cann reaffirmed a “buy” rating and issued a $15.00 price objective (up previously from $6.00) on shares of Verastem in a report on Sunday, December 10th. Oppenheimer reiterated a “buy” rating and set a $15.00 target price on shares of Verastem in a research note on Sunday, December 10th. Zacks Investment Research upgraded Verastem from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 target price on shares of Verastem in a research note on Wednesday, February 7th. Finally, HC Wainwright set a $10.00 target price on Verastem and gave the company a “buy” rating in a research note on Wednesday, December 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $10.14.
Several hedge funds have recently added to or reduced their stakes in the company. AXA raised its position in shares of Verastem by 32.2% during the 4th quarter. AXA now owns 78,425 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 19,118 shares during the last quarter. Northern Trust Corp raised its stake in Verastem by 40.3% in the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 21,178 shares during the period. Wells Fargo & Company MN raised its stake in Verastem by 130.5% in the 4th quarter. Wells Fargo & Company MN now owns 45,987 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 26,036 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Verastem in the 3rd quarter valued at $136,000. Finally, SeaCrest Wealth Management LLC bought a new stake in Verastem in the 4th quarter valued at $108,000. Hedge funds and other institutional investors own 33.22% of the company’s stock.
WARNING: This piece was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3256256/verastem-inc-vstm-forecasted-to-earn-fy2017-earnings-of-1-72-per-share.html.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.